Prenylated Rab acceptor RABAC1 inhibits anti-apoptotic protein BCL2A1 and induces apoptosis
Jong-Tae Kim1, Hee Jun Cho1, Mi-Young Cho2
1Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.
Abstract:
The B cell lymphoma 2 (BCL2) family of proteins constitutes a critical intracellular checkpoint in the intrinsic apoptosis pathway. Among BCL2 members, the anti-apoptotic protein BCL2A1 mediates the resistance to BCL2 inhibitors and may be considered as a target for anti-cancer therapy. Here, we report that prenylated Rab acceptor 1 (RABAC1 or PRA1) inhibits the anti-apoptotic activity of BCL2A1 and induces apoptosis in AGS gastric cancer cells. Protein interaction of BCL2A1 and RABAC1 was verified by an in-vitro glutathione-S-transferase pull-down assay, immunoprecipitation, and confocal microscopy. When apoptosis was induced by cisplatin, the anti-apoptotic activity of BCL2A1 was blocked by RABAC1 expression. RABAC1 caused caspase-3 activation and decreased cell proliferation, clonogenic cell survival, and cell migration and invasion. We suggest RABAC1 as a potential therapeutic target for BCL2A1-related cancer.
Insights
Prenylated Rab acceptor 1 (RABAC1) inhibits the anti-apoptotic BCL2A1 protein, inducing apoptosis in gastric cancer cells. This finding suggests RABAC1 as a potential therapeutic target for BCL2A1-related cancers.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Death Research
Background:
- The B cell lymphoma 2 (BCL2) family regulates apoptosis, with BCL2A1 conferring resistance to BCL2 inhibitors.
- BCL2A1's anti-apoptotic activity makes it a potential target for anti-cancer therapies.
Purpose of the Study:
- To investigate the role of prenylated Rab acceptor 1 (RABAC1) in regulating BCL2A1's anti-apoptotic function.
- To determine if RABAC1 can induce apoptosis in gastric cancer cells.
Main Methods:
- In vitro glutathione-S-transferase pull-down assay
- Immunoprecipitation
- Confocal microscopy
- Caspase-3 activation assays
- Cell proliferation, survival, migration, and invasion assays
Main Results:
- RABAC1 directly interacts with BCL2A1.
- RABAC1 inhibits BCL2A1's anti-apoptotic activity in AGS gastric cancer cells.
- RABAC1 induces caspase-3 activation, decreasing cell proliferation, survival, migration, and invasion.
- RABAC1 blocks BCL2A1's protective effect during cisplatin-induced apoptosis.
Conclusions:
- RABAC1 effectively inhibits the anti-apoptotic protein BCL2A1.
- RABAC1 induces apoptosis and reduces key cancer hallmarks in gastric cancer cells.
- RABAC1 represents a promising therapeutic target for BCL2A1-associated cancers.
Related Concept Videos
Rab Proteins
Rab proteins switch between a cytosolic, GDP-bound inactive state and a membrane-anchored, GTP-bound active state. By themselves, Rabs show slow rates of GDP/GTP exchange and GTP hydrolysis. Thus, Rab proteins are considered...
Rab Cascades
Apoptosis
Feedback Inhibition
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway


